Folic Acid Supplement Versus Placebo for Treating Mucositis Adverse Events in Metastatic Renal Cell Carcinoma Patients Receiving Targeted Therapy

Summary

FASTERCC: Folic acid supplement versus placebo for treating mucositis adverse events in metastatic renal cell carcinoma patients receiving targeted therapy. A randomized, double-blind trial from the Danish renal cancer group (DARENCA study-4)

Eligibility

Target population: Patients with inoperable, locally advanced, or metastatic renal cell carcinoma.

Inclusion Criteria:

1. Patients displaying CTCAE ≥2 mucositis during TKI, mTOR inhibitor or immunotherapy treatment.
2. Signed written informed consent obtained prior to any study specific procedures.
3. Patient must be willing and able to comply with the protocol.
4. Age ≥ 18.
5. Biopsy proven locally advanced or metastatic renal cell carcinoma.
6. Females with a negative serum pregnancy test unless childbearing potential can be otherwise excluded (postmenopausal, hysterectomy or oophorectomy) and not lactating.
7. Fertile women of childbearing potential (\<2 years after last menstruation) and men must use effective means of contraception (oral contraceptives, intrauterine contraceptive device, barrier method of contraception in conjunction with spermicidal jelly or surgical sterilization).
8. Karnofsky Performance status ≥ 60%.

Exclusion Criteria:

1. Known hypersensitivity to folic acid.
2. Use of prednisolone more than 10 mg daily.

Conditions3

Interventions2

Related trials

• "The Effect of Memantine on the Prevention and Amelioration of Paclitaxel-induced Toxicity in Breast Cancer Patients" — Ain Shams University
• A Study of Cardiovascular Events iN Diabetes Plus — University of Oxford
• Aspirin Continuation or Interruption in Patients at Moderate Risk for Cardiovascular Events Undergoing Colonoscopy and/or Polypectomy — Chinese University of Hong Kong
• Aspirin Use for Gastric Cancer Prevention in the Early Gastric Cancer Patients — National Cancer Center, Korea
• Atorvastatin to Reduce Inflammation After Tuberculosis Treatment Completion — University of Cape Town
• Measurement of the Hippocampal Theta Rhythm From the Outer Ear Canal — University of Manitoba
• Prevention of Post-TIPS Hepatic Encephalopathy by Administration of Rifaximin and Lactulose — Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
• Protecting the Kidney's Proximal Tubules From Platinum-Based Chemotherapy Toxicity — Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran

Browse More Trials